Effective Theory of a Dynamically Broken Electroweak Standard Model at NLO

We consider the Standard Model as an effective theory at the weak scale $v$ of a generic new strong interaction that dynamically breaks electroweak symmetry at the energy scale $\Lambda\sim$ (few) TeV. Assuming only the minimal field content with the Standard Model fermions and gauge bosons, but without a light Higgs particle, we construct the complete Lagrangian through next-to-leading order, that is, including terms of order $v^2/\Lambda^2$. The systematics behind this expansion is clarified. Although similar to chiral perturbation theory, it is not governed by the dimension of operators alone, but depends in an essential way on the loop expansion. Power-counting formulas are derived that indicate the classes of operators required at the next-to-leading order. The complete set of operators at leading and next-to-leading order is then listed, based on the restrictions implied by the Standard-Model gauge symmetries. We recover the well-known operators discussed in the literature in connection with the electroweak chiral Lagrangian and in similar contexts, but we collect a complete and systematic list of all terms through order $v^2/\Lambda^2$. This includes some operators not discussed in explicit terms before. We also show that a few of the previously considered operators can be eliminated via the equations of motion. As another important result we confirm the known list of dimension-6 operators in the Standard Model with an elementary Higgs doublet, essentially as a special case of our scenario.Comment: 35 pages, 1 figure; references adde

Phenomenology of non-standard Z couplings in exclusive semileptonic b -> s transitions

The rare decays $B\to K^{(*)}\ell^+\ell^-$, $B\to K^{(*)}\nu\bar\nu$ and $B_s\to\mu^+\mu^-$ are analyzed in a generic scenario where New Physics effects enter predominantly via $Z$ penguin contributions. We show that this possibility is well motivated on theoretical grounds, as the $\bar sbZ$ vertex is particularly susceptible to non-standard dynamics. In addition, such a framework is also interesting phenomenologically since the $\bar sbZ$ coupling is rather poorly constrained by present data. The characteristic features of this scenario for the relevant decay rates and distributions are investigated. We emphasize that both sign and magnitude of the forward-backward asymmetry of the decay leptons in $\bar B\to \bar K^*\ell^+\ell^-$, ${\cal A}^{(\bar B)}_{FB}$, carry sensitive information on New Physics. The observable ${\cal A}^{(\bar B)}_{FB}+{\cal A}^{(B)}_{FB}$ is proposed as a useful probe of non-standard CP violation in $\bar sbZ$ couplings.Comment: Minor modifications; version to appear in Phys. Rev.

Weak Decays Beyond Leading Logarithms

We review the present status of QCD corrections to weak decays beyond the leading logarithmic approximation including particle-antiparticle mixing and rare and CP violating decays. After presenting the basic formalism for these calculations we discuss in detail the effective hamiltonians for all decays for which the next-to-leading corrections are known. Subsequently, we present the phenomenological implications of these calculations. In particular we update the values of various parameters and we incorporate new information on m_t in view of the recent top quark discovery. One of the central issues in our review are the theoretical uncertainties related to renormalization scale ambiguities which are substantially reduced by including next-to-leading order corrections. The impact of this theoretical improvement on the determination of the Cabibbo-Kobayashi-Maskawa matrix is then illustrated in various cases.Comment: 229 pages, 32 PostScript figures (included); uses RevTeX, epsf.sty, rotate.sty, rmpbib.sty (included), times.sty (included; requires LaTeX 2e); complete PostScript version available at ftp://feynman.t30.physik.tu-muenchen.de/pub/preprints/tum-100-95.ps.gz or ftp://feynman.t30.physik.tu-muenchen.de/pub/preprints/tum-100-95.ps2.gz (scaled down and rotated version to print two pages on one sheet of paper

Heavy Quarkonium Effective Theory

We formulate a QCD-based effective theory approach to heavy quarkonia-like systems as $\bar{c} c$ and $\bar{b} b$ resonances and $B_c$ states. We apply the method to inclusive decays, working out a few examples in detail.Comment: 52 pages, LaTeX, 3 uuencoded and compressed figures, uses epsf.sty, CERN-TH.7468/9

Pharmacodynamic evaluation and safety assessment of treatment with antibodies to serum amyloid P component in patients with cardiac amyloidosis: an open-label Phase 2 study and an adjunctive immuno-PET imaging study.

BACKGROUND: In a Phase I study treatment with the serum amyloid P component (SAP) depleter miridesap followed by monoclonal antibody to SAP (dezamizumab) showed removal of amyloid from liver, spleen and kidney in patients with systemic amyloidosis. We report results from a Phase 2 study and concurrent immuno-positron emission tomography (PET) study assessing efficacy, pharmacodynamics, pharmacokinetics, safety and cardiac uptake (of dezamizumab) following the same intervention in patients with cardiac amyloidosis. METHODS: Both were uncontrolled open-label studies. After SAP depletion with miridesap, patients received ≤ 6 monthly doses of dezamizumab in the Phase 2 trial (n = 7), ≤ 2 doses of non-radiolabelled dezamizumab plus [89Zr]Zr-dezamizumab (total mass dose of 80 mg at session 1 and 500 mg at session 2) in the immuno-PET study (n = 2). Primary endpoints of the Phase 2 study were changed from baseline to follow-up (at 8 weeks) in left ventricular mass (LVM) by cardiac magnetic resonance imaging and safety. Primary endpoint of the immuno-PET study was [89Zr]Zr-dezamizumab cardiac uptake assessed via PET. RESULTS: Dezamizumab produced no appreciable or consistent reduction in LVM nor improvement in cardiac function in the Phase 2 study. In the immuno-PET study, measurable cardiac uptake of [89Zr]Zr-dezamizumab, although seen in both patients, was moderate to low. Uptake was notably lower in the patient with higher LVM. Treatment-associated rash with cutaneous small-vessel vasculitis was observed in both studies. Abdominal large-vessel vasculitis after initial dezamizumab dosing (300 mg) occurred in the first patient with immunoglobulin light chain amyloidosis enrolled in the Phase 2 study. Symptom resolution was nearly complete within 24 h of intravenous methylprednisolone and dezamizumab discontinuation; abdominal computed tomography imaging showed vasculitis resolution by 8 weeks. CONCLUSIONS: Unlike previous observations of visceral amyloid reduction, there was no appreciable evidence of amyloid removal in patients with cardiac amyloidosis in this Phase 2 trial, potentially related to limited cardiac uptake of dezamizumab as demonstrated in the immuno-PET study. The benefit-risk assessment for dezamizumab in cardiac amyloidosis was considered unfavourable after the incidence of large-vessel vasculitis and development for this indication was terminated. Trial registration NCT03044353 (2 February 2017) and NCT03417830 (25 January 2018)

Pharmacodynamic evaluation and safety assessment of treatment with antibodies to serum amyloid P component in patients with cardiac amyloidosis: an open-label Phase 2 study and an adjunctive immuno-PET imaging study.

BACKGROUND: In a Phase I study treatment with the serum amyloid P component (SAP) depleter miridesap followed by monoclonal antibody to SAP (dezamizumab) showed removal of amyloid from liver, spleen and kidney in patients with systemic amyloidosis. We report results from a Phase 2 study and concurrent immuno-positron emission tomography (PET) study assessing efficacy, pharmacodynamics, pharmacokinetics, safety and cardiac uptake (of dezamizumab) following the same intervention in patients with cardiac amyloidosis. METHODS: Both were uncontrolled open-label studies. After SAP depletion with miridesap, patients received ≤ 6 monthly doses of dezamizumab in the Phase 2 trial (n = 7), ≤ 2 doses of non-radiolabelled dezamizumab plus [89Zr]Zr-dezamizumab (total mass dose of 80 mg at session 1 and 500 mg at session 2) in the immuno-PET study (n = 2). Primary endpoints of the Phase 2 study were changed from baseline to follow-up (at 8 weeks) in left ventricular mass (LVM) by cardiac magnetic resonance imaging and safety. Primary endpoint of the immuno-PET study was [89Zr]Zr-dezamizumab cardiac uptake assessed via PET. RESULTS: Dezamizumab produced no appreciable or consistent reduction in LVM nor improvement in cardiac function in the Phase 2 study. In the immuno-PET study, measurable cardiac uptake of [89Zr]Zr-dezamizumab, although seen in both patients, was moderate to low. Uptake was notably lower in the patient with higher LVM. Treatment-associated rash with cutaneous small-vessel vasculitis was observed in both studies. Abdominal large-vessel vasculitis after initial dezamizumab dosing (300 mg) occurred in the first patient with immunoglobulin light chain amyloidosis enrolled in the Phase 2 study. Symptom resolution was nearly complete within 24 h of intravenous methylprednisolone and dezamizumab discontinuation; abdominal computed tomography imaging showed vasculitis resolution by 8 weeks. CONCLUSIONS: Unlike previous observations of visceral amyloid reduction, there was no appreciable evidence of amyloid removal in patients with cardiac amyloidosis in this Phase 2 trial, potentially related to limited cardiac uptake of dezamizumab as demonstrated in the immuno-PET study. The benefit-risk assessment for dezamizumab in cardiac amyloidosis was considered unfavourable after the incidence of large-vessel vasculitis and development for this indication was terminated. Trial registration NCT03044353 (2 February 2017) and NCT03417830 (25 January 2018)

Lifetime measurements of the low-lying excited states of ²⁰⁸Po

In this study we present the preliminary results about the lifetimes of the 2₂⁺, 4₁⁺ states of ²⁰⁸Po and the upper limit of the lifetime of the 2₁⁺ state. For measuring the lifetimes of the 2₁⁺ and 4₁⁺ states the Recoil Distance Doppler Shift (RDDS) method and for the lifetime of the 2₂⁺ state the Doppler Shift Attenuation method (DSAM) were used. The resulting absolute transition strength B(M1 ; 2₂⁺ → 2₁⁺) ≥ 0.122(20) μN² reveals the predominant isovector nature of the 2₂⁺ state of ²⁰⁸Po

Randomized clinical trial comparing percutaneous closure of patent foramen ovale (PFO) using the Amplatzer PFO Occluder with medical treatment in patients with cryptogenic embolism (PC-Trial): rationale and design

<p>Abstract</p> <p>Background</p> <p>Several studies have shown an association of cryptogenic stroke and embolism with patent foramen ovale (PFO), but the question how to prevent further events in such patients is unresolved. Options include antithrombotic treatment with warfarin or antiplatelet agents or surgical or endovascular closure of the PFO. The PC-Trial was set up to compare endovascular closure and best medical treatment for prevention of recurrent events.</p> <p>Methods</p> <p>The PC-Trial is a randomized clinical trial comparing the efficacy of percutaneous closure of the PFO using the Amplatzer PFO occluder with best medical treatment in patients with cryptogenic embolism, i.e. mostly cryptogenic stroke. Warfarin for 6 months followed by antiplatelet agents is recommended as medical treatment. Randomization is stratified according to patients age (<45 versus ≥45 years), presence of atrial septal aneurysm (ASA yes or no) and number of embolic events before randomization (one versus more than one event). Primary endpoints are death, nonfatal stroke and peripheral embolism.</p> <p>Discussion</p> <p>patients were randomized in 29 centers of Europe, Canada, and Australia. Randomization started February 2000. Enrollment of 414 patients was completed in February 2009. All patients will be followed-up longitudinally. Follow-up is maintained until the last enrolled patient is beyond 2.5 years of follow-up (expected in 2011).</p> <p>Trial Registration</p> <p>Trial listed in ClinicalTrials.gov as <a href="http://www.clinicaltrials.gov/ct2/show/NCT00166257">NCT00166257</a> and sponsored by AGA Medical, Plymouth, MN, USA</p